Potential new role of the GHSR‑1a‑mediated signaling pathway in cardiac remodeling after myocardial infarction (Review)

Yuan,Ming‑Jie; Huang,He; Huang,Cong‑Xin

doi:10.3892/ol.2014.2245

Potential new role of the GHSR‑1a‑mediated signaling pathway in cardiac remodeling after myocardial infarction (Review)

Authors:
- Ming‑Jie Yuan
- He Huang
- Cong‑Xin Huang
View Affiliations

Affiliations: Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: June 12, 2014 https://doi.org/10.3892/ol.2014.2245
Pages: 969-971

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The gastrointestinal hormone ghrelin has important cardiovascular protective effects, however, its specific mechanisms are not yet completely understood. Recent studies have shown that the ghrelin receptor, growth hormone secretagogue receptor type 1a (GHSR‑1a), regulates cell proliferation, apoptosis and inflammation‑related signaling pathways. In human aortic endothelial cells, ghrelin activates NO production through AMP‑activated protein kinase (AMPK) and Akt activation, and these effects can be blocked by knockdown of GHSR‑1a. Obese mice have been found to exhibit an increased GHSR‑1a content and expression in the heart, associated with an increase in phosphatidylinositol 3‑kinase (PI3K) content and an increase AKT content and phosphorylation. Furthermore, GHSR‑1a expression was observed to be increased in heart failure after myocardial infarction (MI) in rats. Given such complexity in GHSR‑1a signaling and crosstalk with the AMPK and PI3K/Akt signaling pathways, both of which are well‑known factors involved in cardiac remodeling after MI, we speculate that GHSR‑1a signaling may play a regulatory role in cardiac protection and hope to identify new drugs targets. However, to date, no direct association between GHSR‑1a and cardiac remodeling has been found. Therefore, further studies are required.

View Figures

View References

1	Dorn GW II: Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol. 6:283–291. 2009.
2	Deboer MD: The use of ghrelin and ghrelin receptor agonists as a treatment for animal models of disease: efficacy and mechanism. Curr Pharm Des. 18:4779–4799. 2012.
3	Strasser F: Clinical application of ghrelin. Curr Pharm Des. 18:4800–4812. 2012.
4	Kojima M, Hosoda H, Date Y, et al: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 402:656–660. 1999.
5	Isgaard J: Ghrelin and the cardiovascular system. Endocr Dev. 25:83–90. 2013.
6	Baatar D, Patel K and Taub DD: The effects of ghrelin on inflammation and the immune system. Mol Cell Endocrinol. 340:44–58. 2011.
7	Repaci A, Gambineri A, Pagotto U and Pasquali R: Ghrelin and reproductive disorders. Mol Cell Endocrinol. 340:70–79. 2011.
8	Yang J, Liu GQ, Wei R, et al: Ghrelin promotes differentiation of human embryonic stem cells into cardiomyocytes. Acta Pharmacol Sin. 32:1239–1245. 2011.
9	Huang CX, Yuan MJ, Huang H, et al: Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect. Peptides. 30:2286–2291. 2009.
10	Kishimoto I, Tokudome T, Hosoda H, et al: Ghrelin and cardiovascular diseases. J Cardiol. 59:8–13. 2012.
11	Xu X, Ding F, Pang J, et al: Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol. 303:H703–H711. 2012.
12	Mao Y, Tokudome T, Otani K, et al: Ghrelin prevents incidence of malignant arrhythmia after acute myocardial infarction through vagal afferent nerves. Endocrinology. 153:3426–3434. 2012.
13	Yuan MJ, Huang CX, Tang YH, et al: A novel peptide ghrelin inhibits neural remodeling after myocardial infarction in rats. Eur J Pharmacol. 618:52–57. 2009.
14	Gnanapavan S, Kola B, Bustin SA, et al: The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metabol. 87:29882002.
15	Gaytan F, Barreiro ML, Caminos JE, et al: Expression of ghrelin and its functional receptor, the type 1a growth hormone secretagogue receptor, in normal human testis and testicular tumors. J Clin Endocrinol Metab. 89:400–409. 2004.
16	Ghelardoni S, Carnicelli V, Frascarelli S, et al: Ghrelin tissue distribution: comparison between gene and protein expression. J Endocrinol Invest. 29:115–121. 2006.
17	Iglesias MJ, Pineiro R, Blanco M, et al: Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res. 62:481–488. 2004.
18	Nishi Y, Yoh J, Hiejima H and Kojima M: Structures and molecular forms of the ghrelin-family peptides. Peptides. 32:2175–2182. 2011.
19	Chen C, Wu D and Clarke IJ: Signal transduction systems employed by synthetic GH-releasing peptides in somatotrophs. J Endocrinol. 148:381–386. 1996.
20	Lodeiro M, Theodoropoulou M, Pardo M, et al: c-Src regulates Akt signaling in response to ghrelin via beta-arrestin signaling-independent and -dependent mechanisms. PLoS One. 4:e46862009.
21	Camiña JP, Lodeiro M, Ischenko O, et al: Stimulation by ghrelin of p42/p44 mitogen-activated protein kinase through the GHS-R1a receptor: role of G-proteins and beta-arrestins. J Cell Physiol. 213:187–200. 2007.
22	Wang Y, Narsinh K, Zhao L, et al: Effects and mechanisms of ghrelin on cardiac microvascular endothelial cells in rats. Cell Biol Int. 35:135–140. 2011.
23	Chen JH, Huang SM, Chen CC, et al: Ghrelin induces cell migration through GHS-R, CaMKII, AMPK, and NF-κB signaling pathway in glioma cells. J Cell Biochem. 112:2931–2941. 2011.
24	Holliday ND, Holst B, Rodionova EA, et al: Importance of constitutive activity and arrestin-independent mechanisms for intracellular trafficking of the ghrelin receptor. Mol Endocrinol. 21:3100–3112. 2007.
25	Iantorno M, Chen H, Kim JA, et al: Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells. Am J Physiol Endocrinol Metab. 292:E756–E764. 2007.
26	Xu X, Jhun BS, Ha CH and Jin ZG: Molecular mechanisms of ghrelin-mediated endothelial nitric oxide synthase activation. Endocrinology. 149:4183–4192. 2008.
27	Chen X, Chen Q, Wang L and Li G: Ghrelin induces cell migration through GHSR1a-mediated PI3K/Akt/eNOS/NO signaling pathway in endothelial progenitor cells. Metabolism. 62:743–752. 2013.
28	Lacerda-Miranda G, Soares VM, Vieira AK, et al: Ghrelin signaling in heart remodeling of adult obese mice. Peptides. 35:65–73. 2012.
29	Ma Y, Zhang L, Edwards JN, et al: Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium. PLoS One. 7:e352652012.
30	Kanashiro-Takeuchi RM, Takeuchi LM, Rick FG, et al: Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc Natl Acad Sci USA. 109:559–563. 2012.
31	Kanashiro-Takeuchi RM, Tziomalos K, Takeuchi LM, et al: Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci USA. 107:2604–2609. 2010.
32	Casanueva FF, Camina JP, Carreira MC, et al: Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a. Proc Natl Acad Sci USA. 105:20452–20457. 2008.
33	Beiras-Fernandez A, Kreth S, Weis F, et al: Altered myocardial expression of ghrelin and its receptor (GHSR-1a) in patients with severe heart failure. Peptides. 31:2222–2228. 2010.
34	Buss SJ, Riffel JH, Malekar P, et al: Chronic Akt blockade aggravates pathological hypertrophy and inhibits physiological hypertrophy. Am J Physiol Heart Circ Physiol. 302:H420–H430. 2012.
35	Chen LL, Zhu TB, Yin H, et al: Inhibition of MAPK signaling by eNOS gene transfer improves ventricular remodeling after myocardial infarction through reduction of inflammation. Mol Biol Rep. 37:3067–3072. 2010.